NCT05988814 (FOLFIRINOX3 P) is a Phase 2 clinical trial of FOLFIRINOX treatment in Metastatic Pancreatic Cancer, sponsored by Centre Georges Francois Leclerc.

Who is sponsoring NCT05988814?

NCT05988814 is sponsored by Centre Georges Francois Leclerc.

What drugs are being tested in NCT05988814?

Interventions in NCT05988814: FOLFIRINOX treatment.

What condition does NCT05988814 study?

NCT05988814 studies Metastatic Pancreatic Cancer.

Is NCT05988814 still recruiting?

NCT05988814 is currently recruiting now. Last updated 12 February 2024.

Last reviewed 2024-02-12 · How we verify

NCT05988814: FOLFIRINOX3 P

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

Recruiting now Phase 2 Last updated 12 February 2024

What this trial tests

Phase 2 trial testing FOLFIRINOX treatment in Metastatic Pancreatic Cancer in 90 participants. Currently enrolling.

Timeline

24 January 2024

Primary endpoint
24 July 2029

24 July 2029

Quick facts

Lead sponsor	Centre Georges Francois Leclerc
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	24 January 2024
Primary completion	24 July 2029
Estimated completion	24 July 2029
Sites	1 location across France

Drugs / interventions tested

FOLFIRINOX treatment — full drug profile →

Conditions studied

Metastatic Pancreatic Cancer — all drugs for Metastatic Pancreatic Cancer →

Sponsor

Centre Georges Francois Leclerc — full company profile →

Who can join

18 and older, any sex, with Metastatic Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate the efficacy of treatment FOLFORINOX 3 in first-line therapy for patients with locally advanced unresectable or metastatic pancreatic cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Metastatic Pancreatic Cancer

Currently open trials in the same condition.

NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT06843551 — The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation · Phase 2 · recruiting
NCT06951997 — QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer · Phase 2 · recruiting
NCT06533332 — A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors · Phase 1 · recruiting

Other Centre Georges Francois Leclerc trials

Trials by the same sponsor.

NCT07575854 — A Study of Selective Internal Radiation Therapy for the Management of Chemotherapy-induced Thrombocytopenia With Splenom · NA · not yet recruiting
NCT07413627 — A Study Evaluating the Contribution of Non-Coplanar Beam Arrangement in Reducing Toxicity in Radiotherapy for Upper Aero · NA · not yet recruiting
NCT07376512 — Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis · not yet recruiting
NCT07093593 — Emergence of Bacterial Resistance to Antibiotics in the Digestive Microbiota of Patients Treated With Anticancer Drugs · NA · not yet recruiting
NCT06944548 — Evaluation of the Effect of Adapted Physical Activity on the Modification of Lipid Metabolism During Chemotherapy for Me · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05988814 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Georges Francois Leclerc
Last refreshed: 12 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05988814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing